• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Annexon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/12/25 4:05:15 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANNX alert in real time by email
    8-K
    false000152811500015281152025-05-122025-05-12

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 12, 2025

     

     

    ANNEXON, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    001-39402

    27-5414423

    (State or other jurisdiction

    (Commission

    (IRS Employer

    of incorporation)

    File Number)

    Identification No.)

     

     

    1400 Sierra Point Parkway, Bldg C, Suite 200

    Brisbane, California 94005

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 822-5500

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share

    ANNX

    The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 2.02. Results of Operations and Financial Condition.

    On May 12, 2025, Annexon, Inc. (the “Company”) announced certain financial results for the first quarter ended March 31, 2025. A copy of the Company’s press release, titled “Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

    The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

    Item 9.01. Financial Statements and Exhibits.

    (d)
    Exhibits.

     

    Exhibit

     

    Description

     

     

     

    99.1

     

    Press Release, dated May 12, 2025, titled “Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones”

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: May 12, 2025

    Annexon, Inc.

    By:

    /s/ Jennifer Lew

    Jennifer Lew

    Executive Vice President and Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    Get the next $ANNX alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ANNX

    DatePrice TargetRatingAnalyst
    3/1/2024$11.00Neutral → Overweight
    JP Morgan
    12/21/2023$4.00 → $6.00Neutral → Buy
    BofA Securities
    10/30/2023$11.00Overweight
    Wells Fargo
    5/26/2023$8.00 → $3.00Buy → Neutral
    BofA Securities
    5/25/2023$19.00 → $9.00Overweight → Neutral
    JP Morgan
    9/16/2022$12.00Buy
    Jefferies
    9/9/2022$15.00Buy
    BTIG Research
    11/30/2021$40.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ANNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Annexon upgraded by JP Morgan with a new price target

      JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00

      3/1/24 7:27:25 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon upgraded by BofA Securities with a new price target

      BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously

      12/21/23 6:41:39 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Annexon with a new price target

      Wells Fargo initiated coverage of Annexon with a rating of Overweight and set a new price target of $11.00

      10/30/23 7:48:24 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    SEC Filings

    See more
    • SEC Form 8-K filed by Annexon Inc.

      8-K - Annexon, Inc. (0001528115) (Filer)

      6/25/25 4:35:12 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Annexon Inc.

      8-K - Annexon, Inc. (0001528115) (Filer)

      6/9/25 4:05:52 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Annexon Inc.

      10-Q - Annexon, Inc. (0001528115) (Filer)

      5/12/25 4:10:27 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

      Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-medi

      6/18/25 4:05:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Biosciences to Present at the Jefferies Global Healthcare Conference

      BRISBANE, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that Douglas Love, president and chief executive officer, will present at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:10 a.m. EST. A live webcast of the event can be accessed under the ‘Events & Presentations' section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presenta

      5/29/25 4:05:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

      First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentations on New Pivotal Phase 3 Analyses Underscore Tanruprubart's Rapid and Sustained Treatment Effect and Improvement in Quality of Life Compared to Placebo BRISBANE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, toda

      5/19/25 4:05:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Carson William H. bought $10,123 worth of shares (4,115 units at $2.46), increasing direct ownership by 16% to 29,715 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      7/1/25 4:55:13 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carson William H. bought $17,056 worth of shares (3,200 units at $5.33), increasing direct ownership by 14% to 25,600 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      12/4/24 6:12:46 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Carson William H. bought $19,104 worth of shares (3,200 units at $5.97), increasing direct ownership by 17% to 22,400 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      10/2/24 4:15:17 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Carson William H. bought $10,123 worth of shares (4,115 units at $2.46), increasing direct ownership by 16% to 29,715 units (SEC Form 4)

      4 - Annexon, Inc. (0001528115) (Issuer)

      7/1/25 4:55:13 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Wiggans Thomas G

      4 - Annexon, Inc. (0001528115) (Issuer)

      6/9/25 4:30:32 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Satter Muneer A

      4 - Annexon, Inc. (0001528115) (Issuer)

      6/9/25 4:27:12 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Leadership Updates

    Live Leadership Updates

    See more
    • Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

      Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-medi

      6/18/25 4:05:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

      Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

      4/9/25 7:00:00 AM ET
      $ANNX
      $LUMO
      $GRAY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Expands Board of Directors with Appointment of Commercial Executive William "BJ" Jones

      BRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced the appointment of  William "BJ" Jones to its board of directors. Mr. Jones brings 30 years of U.S. and global commercial and launch experience in the biotechnology industry. "We are thrilled to add BJ to our board of directors at this transformative time for Annexon," said Douglas Love, president and chief executive officer of Annexon. "His deep commercial expertise and proven experience

      1/10/25 8:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 7:21:59 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 6:46:41 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Annexon Inc.

      SC 13G/A - Annexon, Inc. (0001528115) (Subject)

      11/14/24 5:30:27 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ANNX
    Financials

    Live finance-specific insights

    See more
    • Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

      Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the

      12/16/24 7:30:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

      Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther

      6/4/24 7:00:00 AM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data

      BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating inflammatory-related diseases, today announced that it will host a conference call and webcast on Tuesday, June 4, 2024, at 8:30 a.m. ET to discuss GBS phase 3 data. Conference Call and Webcast InformationThe live webcast and replay may be accessed by visiting Annexon's website here. The dial-in number is 1-877-407-0784 (U.S./Canada) or 1-201-689-8560 (international). The conference ID for all callers is 13747058. The Call me™ link may be accessed here. Participants can use guest

      6/3/24 4:30:00 PM ET
      $ANNX
      Biotechnology: Pharmaceutical Preparations
      Health Care